LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

Search

Clearside Biomedical Inc

Chiusa

0.88 4.76

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.84

Massimo

0.89

Metriche Chiave

By Trading Economics

Entrata

383K

-7.3M

Vendite

-732K

306K

EPS

-0.1

Margine di Profitto

-2,387.582

Dipendenti

32

EBITDA

508K

-4.6M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+574.42% upside

Dividendi

By Dow Jones

Utili prossimi

14 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-9.5M

69M

Apertura precedente

-3.88

Chiusura precedente

0.88

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

Clearside Biomedical Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 mag 2025, 22:34 UTC

Acquisizioni, Fusioni, Takeovers

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12 mag 2025, 23:48 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Technical Recovery -- Market Talk

12 mag 2025, 23:46 UTC

Discorsi di Mercato

Nikkei Likely to Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

12 mag 2025, 23:34 UTC

Discorsi di Mercato

Trade Deal Lowers US Recession Risks to 35% -- Market Talk

12 mag 2025, 23:21 UTC

Discorsi di Mercato

US-China Trade Deal Still Risks Stagflation; Supply Chain Disruption -- Market Talk

12 mag 2025, 22:54 UTC

Discorsi di Mercato

Australian Treasurer Warns Uncertainty Will Still Dominate Markets -- Market Talk

12 mag 2025, 22:43 UTC

Utili

Telefonica Brasil 1Q EPS BRL0.65 >VIV

12 mag 2025, 22:14 UTC

Notizie principali

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mag 2025, 22:08 UTC

Acquisizioni, Fusioni, Takeovers

Ampol Expects Replacement-Cost Ebitda Uplift by Run Rate at End-2025 of Around A$30 Million/Year

12 mag 2025, 22:08 UTC

Acquisizioni, Fusioni, Takeovers

Ampol Expects Pretax Proceeds of Around A$65 Million From Transactions

12 mag 2025, 22:07 UTC

Acquisizioni, Fusioni, Takeovers

Ampol to Sell Australia Retail Electricity Business for Nominal Sum

12 mag 2025, 22:07 UTC

Acquisizioni, Fusioni, Takeovers

Ampol to Sell Australia Retail Electricity Business to AGL

12 mag 2025, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

Meridian to Take on Flick, Z Energy Branded Electricity Customers

12 mag 2025, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

Meridian Energy to Buy Business From Ampol for NZ$70 Million

12 mag 2025, 22:05 UTC

Acquisizioni, Fusioni, Takeovers

Ampol to Sell New Zealand Electricity Retailing Businesses to Meridian Energy

12 mag 2025, 22:04 UTC

Acquisizioni, Fusioni, Takeovers

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12 mag 2025, 21:15 UTC

Notizie principali

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- 2nd update -- WSJ

12 mag 2025, 21:01 UTC

Utili

Constellation Software 1Q Rev $2.65B >CSU.T

12 mag 2025, 21:01 UTC

Utili

Constellation Software 1Q Net $115M >CSU.T

12 mag 2025, 21:01 UTC

Utili

Constellation Software 1Q EPS $5.44 >CSU.T

12 mag 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

12 mag 2025, 20:50 UTC

Discorsi di Mercato
Utili

Basic Materials Roundup: Market Talk

12 mag 2025, 20:44 UTC

Notizie principali

Trade Thaw Sparks Stock Rally, Leaves Wall Street Cautious -- WSJ

12 mag 2025, 20:31 UTC

Notizie principali

How to Think About the Stock Market When Earnings Guidance Becomes Meaningless -- Heard on the Street -- UPDATED -- WSJ

12 mag 2025, 20:24 UTC

Utili

Energy Vault Holdings: Encouraging News on China/U.S. Tariff Pause, Pending Final Positive Resolution and Timing >NRGV

12 mag 2025, 20:24 UTC

Utili

Energy Vault Holdings: No Change to Current Guidance, With Potential Rev Upside on Accelerated U.S. Battery Deliveries in 2025 >NRGV

12 mag 2025, 20:24 UTC

Notizie principali

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- WSJ

12 mag 2025, 20:22 UTC

Acquisizioni, Fusioni, Takeovers

Spirit AeroSystems Holdings: IRS Rules That Sale to Boeing Will Qualify as a Reorganization Under Section 368(a)(1)(B)

12 mag 2025, 20:15 UTC

Utili

Rigetti Computing Reports Earnings. How the Company Takes a Different Approach to Quantum. -- Barrons.com

12 mag 2025, 20:10 UTC

Utili

Blink Charging 1Q Rev $20.8M >BLNK

Confronto tra pari

Modifica del prezzo

Clearside Biomedical Inc Previsione

Obiettivo di Prezzo

By TipRanks

574.42% in crescita

Previsioni per 12 mesi

Media 5.8 USD  574.42%

Alto 8 USD

Basso 4 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Clearside Biomedical Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

5

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.8417 / 0.8939Supporto e resistenza

A breve termine

Neutral Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Weak Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.